By inhibiting the activation of JAK/STAT-associated signaling pathways and modulating the release of various inflammatory mediators, it can ameliorate airway inflammation, influence skin barrier integrity, and restore the pathological condition of the gastric mucosa, thereby yielding a favorable therapeutic outcome for pulmonary disorders, inflammatory dermatoses, gastrointestinal ailments, and more (36–38). This evidence concerns the gene SOAT1 and lung disorder.